Bristol-Myers (BMY) Director Phyllis Yale Acquires 776 DSUs

Phyllis R. Yale, a director of Bristol-Myers Squibb Company (BMY), reported a transaction dated 09/30/2025 on a Form 4.

Accepted by SEC EDGAR 10/02/2025 - 06:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Phyllis R. Yale, a director of Bristol-Myers Squibb Company (BMY), reported a transaction dated 09/30/2025 on a Form 4. The filing shows acquisition of 776.053 Deferred Share Units which will convert to shares of common stock upon settlement. After this transaction the reporting person beneficially owned 37,734.687 shares, a total that the filing says includes deferred compensation and dividends reinvested. The reported price for the deferred units is $0. The Form 4 is signed by an attorney-in-fact on behalf of Ms. Yale and dated 10/02/2025.

Positive

• Director ownership increased to 37,734.687 shares following the reported transaction
• Acquisition recorded of 776.053 Deferred Share Units that will convert to common stock upon settlement
• Disclosure includes reinvested dividends, indicating accumulated deferred compensation is captured

Negative

• None.

Insights

Corporate Governance Expert

Director deferred-compensation units increased director stake to 37,734.687 shares.

This Form 4 records a non-derivative acquisition of 776.053 Deferred Share Units on 09/30/2025 that the filer states will convert into common stock upon settlement. The filing explicitly notes the reported beneficial ownership after the transaction is 37,734.687 shares and that this total includes deferred compensation and dividends reinvested.

The transaction is routine director compensation reporting rather than a market purchase; the Form lists a $0 price for the units. This is administrative disclosure of ownership and does not by itself state any open-market trading or change in control.

Insider Trade Summary

Grant/Award: 776.053 shares

Grant/Award 1 txn

Insider YALE PHYLLIS R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	776.053	$0.00	$0.00

Holdings After Transaction: Deferred Share Units — 37,734.687 contracts (Direct)

Footnotes (2)

1. F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
2. F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Phyllis R. Yale report on Form 4 for BMY?

The Form 4 reports acquisition of 776.053 Deferred Share Units on 09/30/2025, increasing beneficial ownership to 37,734.687 shares.

Do the Deferred Share Units convert to Bristol-Myers (BMY) common stock?

Yes. The filing states each Deferred Share Unit will be converted into a share of common stock upon settlement.

What price was reported for the Deferred Share Units?

The Form 4 reports a price of $0 for the Deferred Share Units.

Does the filing indicate the ownership includes other compensation?

Yes. The filing explicitly says the 37,734.687 shares include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact for Phyllis R. Yale on 10/02/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

YALE PHYLLIS R

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	09/30/2025		A		776.053		(1)	(1)	Common Stock, $0.10 par value	776.053	$0	37,734.687(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Sophie M. Bail, attorney-in-fact for Phyllis R. Yale	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.